CHROMADEX CORP (CDXC) Stock Fundamental Analysis

NASDAQ:CDXC • US1710774076

7.87 USD
-0.07 (-0.88%)
At close: Mar 18, 2025
7.87 USD
0 (0%)
After Hours: 3/18/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to CDXC. CDXC was compared to 58 industry peers in the Life Sciences Tools & Services industry. CDXC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDXC is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year CDXC was profitable.
  • CDXC had a positive operating cash flow in the past year.
  • CDXC had negative earnings in 4 of the past 5 years.
  • In multiple years CDXC reported negative operating cash flow during the last 5 years.
CDXC Yearly Net Income VS EBIT VS OCF VS FCFCDXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • CDXC has a better Return On Assets (12.52%) than 90.91% of its industry peers.
  • CDXC's Return On Equity of 18.55% is amongst the best of the industry. CDXC outperforms 90.91% of its industry peers.
  • The Return On Invested Capital of CDXC (12.13%) is better than 89.09% of its industry peers.
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROIC 12.13%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
CDXC Yearly ROA, ROE, ROICCDXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.58%, CDXC is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
  • With a decent Operating Margin value of 7.76%, CDXC is doing good in the industry, outperforming 63.64% of the companies in the same industry.
  • CDXC has a Gross Margin of 61.84%. This is amongst the best in the industry. CDXC outperforms 87.27% of its industry peers.
  • CDXC's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
CDXC Yearly Profit, Operating, Gross MarginsCDXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CDXC is creating some value.
  • Compared to 1 year ago, CDXC has more shares outstanding
  • CDXC has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CDXC has an improved debt to assets ratio.
CDXC Yearly Shares OutstandingCDXC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDXC Yearly Total Debt VS Total AssetsCDXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 15.46 indicates that CDXC is not in any danger for bankruptcy at the moment.
  • CDXC's Altman-Z score of 15.46 is amongst the best of the industry. CDXC outperforms 100.00% of its industry peers.
  • There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.46
ROIC/WACC1.11
WACC10.97%
CDXC Yearly LT Debt VS Equity VS FCFCDXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
  • CDXC's Current ratio of 3.57 is in line compared to the rest of the industry. CDXC outperforms 54.55% of its industry peers.
  • A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
  • The Quick ratio of CDXC (3.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.06
CDXC Yearly Current Assets VS Current LiabilitesCDXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 242.86% over the past year.
  • The Revenue has grown by 19.17% in the past year. This is quite good.
  • Measured over the past years, CDXC shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%

3.2 Future

  • CDXC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.55% yearly.
  • Based on estimates for the next years, CDXC will show a quite strong growth in Revenue. The Revenue will grow by 19.24% on average per year.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDXC Yearly Revenue VS EstimatesCDXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CDXC Yearly EPS VS EstimatesCDXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 78.70 indicates a quite expensive valuation of CDXC.
  • Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
  • CDXC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.99.
  • CDXC is valuated quite expensively with a Price/Forward Earnings ratio of 66.13.
  • CDXC's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, CDXC is valued quite expensively.
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
CDXC Price Earnings VS Forward Price EarningsCDXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 61.82% of the companies in the same industry are more expensive than CDXC, based on the Enterprise Value to EBITDA ratio.
  • CDXC's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CDXC is cheaper than 65.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 51.22
EV/EBITDA 66.44
CDXC Per share dataCDXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of CDXC may justify a higher PE ratio.
  • A more expensive valuation may be justified as CDXC's earnings are expected to grow with 43.55% in the coming years.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CDXC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CHROMADEX CORP

NASDAQ:CDXC (3/18/2025, 8:00:02 PM)

After market: 7.87 0 (0%)

7.87

-0.07 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04
Earnings (Next)05-06
Inst Owners30.29%
Inst Owner Change1.22%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
P/S 6.14
P/FCF 51.22
P/OCF 50.53
P/B 13.27
P/tB 13.38
EV/EBITDA 66.44
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROCE 15.35%
ROIC 12.13%
ROICexc 104.84%
ROICexgc 111.73%
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
FCFM 11.99%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 20.02%
Cap/Sales 0.16%
Interest Coverage 7726
Cash Conversion 141.79%
Profit Quality 139.72%
Current Ratio 3.57
Quick Ratio 3.06
Altman-Z 15.46
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A

CHROMADEX CORP / CDXC FAQ

What is the fundamental rating for CDXC stock?

ChartMill assigns a fundamental rating of 6 / 10 to CDXC.


Can you provide the valuation status for CHROMADEX CORP?

ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.


Can you provide the profitability details for CHROMADEX CORP?

CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.


Can you provide the financial health for CDXC stock?

The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.


What is the expected EPS growth for CHROMADEX CORP (CDXC) stock?

The Earnings per Share (EPS) of CHROMADEX CORP (CDXC) is expected to grow by 19% in the next year.